Overview

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
EMS
Treatments:
Dapagliflozin
Linagliptin